Asthma Maintenance Therapy Based on GINA Guidelines

Preferred Treatment Strategy: ICS-Formoterol Combination

The Global Initiative for Asthma (GINA) recommends low-dose inhaled corticosteroid (ICS) combined with formoterol as both maintenance and reliever therapy (SMART approach) for patients with mild to moderate controlled asthma, as the preferred strategy 1, 2
The American Thoracic Society and the European Respiratory Society support the use of ICS-containing treatment as the cornerstone of asthma maintenance therapy, which reduces airway inflammation, improves symptoms, lung function, and quality of life while preventing severe exacerbations and asthma-related mortality 1, 2

For patients who cannot access or prefer not to use ICS-formoterol combinations, the National Asthma Education and Prevention Program recommends low-dose ICS twice daily with as-needed short-acting beta-agonist (SABA) for symptom relief 2
The American College of Allergy, Asthma, and Immunology suggests that this approach is the most effective single long-term controller medication, superior to leukotriene modifiers, theophylline, or cromones 2

The American Academy of Allergy, Asthma, and Immunology recommends using a spacer or valved holding chamber with metered-dose inhalers to reduce oropharyngeal deposition and minimize local side effects like oral candidiasis 2
The European Respiratory Society instructs patients to rinse mouth and spit after each ICS inhalation to further reduce thrush risk 2

The Global Initiative for Asthma (GINA) assesses treatment response within 2-6 weeks of initiation or dose adjustment, and well-controlled asthma requires: daytime symptoms ≤2 days/week, no nighttime awakenings, reliever use ≤2 days/week, and no activity limitation over the past 4 weeks 1, 2
The National Asthma Education and Prevention Program recommends stepping down therapy after 2-4 months of sustained control to the minimum dose maintaining control, monitoring for at least 3 months before further reduction 2

The American Thoracic Society and the European Respiratory Society recommend adding a long-acting beta-agonist (LABA) to low-dose ICS rather than increasing ICS dose alone, as this provides greater improvement in lung function, symptoms, and exacerbation reduction 2
The American College of Allergy, Asthma, and Immunology advises never using LABA as monotherapy, as this increases risk of severe exacerbations and asthma-related deaths; LABAs must always be combined with ICS 1, 2

The National Asthma Education and Prevention Program warns against relying on SABA-only therapy for persistent asthma, as using SABA more than 2-3 times daily indicates inadequate control and need for anti-inflammatory therapy 2, 4
The American Academy of Allergy, Asthma, and Immunology cautions against increasing ICS dose short-term for worsening symptoms in adherent patients with mild-moderate asthma, as controlled trials show no benefit 2, 3

The European Respiratory Society notes that budesonide/formoterol is the most extensively studied ICS-formoterol combination for SMART therapy; other ICS combinations theoretically could work but lack supporting evidence 3
The American Thoracic Society mentions that SMART is currently off-label use in the United States, though the boxed warning regarding asthma-related death has been removed from ICS/LABA labels 3